Salus Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2020

Location

Shenzhen Guangdong China

Primary Industry

Medical Devices & Equipment

About

Founded in 2020 and based in Shenzhen, China, Salus is a biotech medical company that focuses on R&D of sequencing and spatial omics platforms. It cooperated with universities and enterprises such as Sun Yat-sen University and Shenzhen Institute of Synthetic Biology. Luyang Zhao, the founder and the CEO of the company, was a senior VP at QIELOU Capital and a senior analyst at GTJA Investment Group. In December 2023, it raised series A funding. The company's main products include Sequencers, Spatial Omics Scopes, and Kits and Reagents. Sequencers provide throughput, sequencing and data export services based on Salus microarray, enzyme and chemical reagent technology. Its products can be used in non-invasive prenatal genetic testing, microbial testing, tumor diagnosis and treatment, assisted reproduction and other fields. The company will use the funding for the R&D and registration filing of gene sequencing platform and spatial genomics products.

Current Investors

ZhenFund, SH Pinnacles, Wedge Investment

Request a demo to show more

Primary Industry

Medical Devices & Equipment

Sub Industries

Molecular Science, Genetics & Gene Therapy, Diagnostic Equipment, Monitoring Equipment

Website

www.salus-bio.com

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.